| Literature DB >> 25875842 |
Madiha Kanwal1, Saadia Alyas1, Muhammad Afzal1, Atika Mansoor2, Rashda Abbasi2, Flora Tassone3, Sajid Malik1, Kehkashan Mazhar2.
Abstract
Fragile-X syndrome (FXS) is the most common form of inherited intellectual disability (ID) and affects 0.7-3.0% of intellectually compromised population of unknown etiology worldwide. It is mostly caused by repeat expansion mutations in the FMR1 at chromosome Xq27.3. The present study aimed to develop molecular diagnostic tools for a better detection of FXS, to assess implementation of diagnostic protocols in a developing country and to estimate the prevalence of FXS in a cohort of intellectually disabled subjects from Pakistan. From a large pool of individuals with below normal IQ range, 395 subjects with intellectual disability of unknown etiology belonging to different regions of the country were recruited. Conventional-PCR, modified-PCR and Southern blot analysis methods were employed for the detection of CGG repeat polymorphisms in the FMR1 gene. Initial screening with conventional-PCR identified 13 suspected patients. Subsequent investigations through modified PCR and Southern blot analyses confirmed the presence of the FMR1 mutation, suggesting a prevalence of 3.5% and 2.8% (mean 3.3%) among the male and female ID patients, respectively. These diagnostic methods were further customized with the in-house conditions to offer robust screening of referral patients/families for diagnostics and genetic counseling. Prescreening and early diagnosis are crucial for designing a prudent strategy for the management of subjects with ID. Outcome of the study recommends health practitioners for implementation of molecular based FXS diagnosis in routine clinical practice to give a better care for patients similar to the ones included in the study.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25875842 PMCID: PMC4396850 DOI: 10.1371/journal.pone.0122213
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Survey plan for screening of subjects.
Clinical features of subjects with ID of unknown origin (n = 395, confirmed FXS = 13).
| Symptoms Reported | Symptoms Not Present n(%) | Symptoms Present n(%) | Confirmed FXS Subjects n(%) |
|---|---|---|---|
| Hyperactivity | 15 ( | 329 ( | 9( |
| Tactilely defensive | 56 ( | 266 ( | 5 ( |
| Hand flapping | 162 ( | 167 ( | 5 ( |
| Hand biting | 140 ( | 192 ( | 4 ( |
| Poor eye contact | 205 ( | 134 ( | 8 ( |
| Speech disorder | 64 ( | 251 ( | 8 ( |
| Hyper extensible MP | 158( | 59 ( | 2 ( |
| Facial features | 47 ( | 339 ( | 6 ( |
| - Long face | 226 ( | 113 ( | 5 ( |
| - Prominent forehead | 298 ( | 41 ( | 3 ( |
| - Prominent jaw | 278 ( | 61 ( | 6 ( |
| - Prominent/long ears | 215 ( | 124 ( | 6 ( |
| Families with more than one affected individual | 298 ( | 26 ( | 6 ( |
* metacarpophalangeal.
Fig 2Facial features of unrelated Fragile X patients.
Fig 3Selected pedigrees of FXS patients.
Analyzed patients and carrier mothers are given identification numbers.
Fig 4A. Primer pair 1 PCR amplification products of FXS negative subjects (lanes 1–5).
Agarose gel electrophoresis results of methylation specific PCR. B. Primer pair 3 gave amplification product of ~80bp of FXS positive subjects (lanes 2–4). C. Primer pair 4 did not give amplification of the FXS positive subjects (lanes 2&3) but yielded a product of ~300bp with FXS negative subjects (lane 4).
Fig 5Southern blot analysis shows a normal female control (lane 2); premutation carrier females (lanes 3 and 7); methylation mosaic male (lane 4); full mutation female (lane 5); size mosaic males (lanes 6 and 8).
1kb DNA size marker is shown in lane 1.